National reference center for gestational trophoblastic disease in France
The French National Reference Centre of Gestational Trophoblastic Disease
This study is about a special center in France that helps women with gestational trophoblastic disease by providing treatment and support while allowing them to stay connected with their local doctors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25500 (estimated) |
| Sex | Female |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Pierre-Bénite) |
| Trial ID | NCT02892877 on ClinicalTrials.gov |
What this trial studies
This initiative focuses on the registration, monitoring, and treatment of women diagnosed with gestational trophoblastic disease (GTD) in France. The center operates on a multidisciplinary approach, allowing patients to remain under the care of their local physician while also accessing specialized treatment at the center. Approximately 850 new cases are registered annually, with 140 women receiving treatment, primarily through chemotherapy and surgery. The center collaborates with local expert teams to provide comprehensive care and support for patients diagnosed with various forms of trophoblastic disease.
Who should consider this trial
Good fit: Ideal candidates for this initiative are women with a histologically proven diagnosis of trophoblastic disease or gestational trophoblastic neoplasia.
Not a fit: Patients without a confirmed diagnosis of trophoblastic disease will not benefit from this initiative.
Why it matters
Potential benefit: If successful, this initiative could significantly enhance the management and treatment outcomes for women with gestational trophoblastic disease.
How similar studies have performed: Other studies have shown success in managing gestational trophoblastic disease through specialized centers, indicating that this approach is supported by prior evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients are eligible if they have a histologically proven trophoblastic disease, or a diagnosis of gestational trophoblastic neoplasia done on an abnormal evolution of hCG Exclusion Criteria: * none
Where this trial is running
Pierre-Bénite
- Centre des Maladies Trophoblastiques Centre Hospitalier Lyon Sud-Bâtiment 3B-2ème étage, 165 Chemin du Grand Revoyet — Pierre-Bénite, France (Recruiting)
Study contacts
- Principal investigator: François Golfier, Pr — Centre National de Référence des maladies trophoblastiques Centre Hospitalier Lyon Sud - Hospices Civils de Lyon
- Study coordinator: François Golfier, Pr
- Email: francois.golfier@chu-lyon.fr
- Phone: (0)4 78 86 66 78
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.